ABMED · GLOBAL REGULATORY & MARKET ACCESS

Australia and New Zealand

Assess the TGA/ARTG pathway and Medsafe/WAND notification separately.

Two markets, distinct responsibilities

Illustrative Sydney harbour landscape

Australia · TGA and ARTG

Assess device or IVD classification, exemptions and the applicable ARTG inclusion route. Australian Sponsor responsibility, manufacturer conformity evidence and application audit are separate matters.

Confirm the Sponsor, kind-of-device grouping, manufacturer conformity evidence and any application audit. ARTG exemptions and the treatment of different device/IVD classes must be assessed individually.

Illustrative New Zealand landscape

New Zealand · Medsafe and WAND

WAND is a notification database, not a product approval. Assess device scope and exemptions, the actual New Zealand Sponsor and the applicable notification and maintenance duties.

Assess the actual NZ Sponsor and applicable notification exemption; the relevant notification period is generally within 30 calendar days of becoming the Sponsor. Retain safety/performance evidence and maintain information, complaints, traceability and recall arrangements.

Practical scope

ABMED Testing Company

Testing consultation and exploratory test planning: define test plans, applicable standards and acceptance criteria, and match suitable laboratories.

ABMED Clinical Company

Clinical evidence work: CR strategy, equivalence assessment, database literature searches and screening, testing/simulated-use planning and laboratory coordination, CER and PMCF plans.

ABMED Enterprise Management Company

Quality-system training, gap analysis, development and implementation, and integrated systems covering NMPA inspections, ISO 13485, FDA QMSR and inspection readiness, and ISO 15378.

Official references

TGA device inclusion process ↗

Medsafe explanation of WAND ↗